Over a seven-year follow-up, the study found a significantly reduced pancreatic cancer incidence among GLP-1 RA users (0.14%) compared to non-users (0.20%), corresponding to a 31% reduced risk (risk ratio [RR]: 0.69; 95% CI: 0.639-0.752; p < 0.0001) [21]. Here, GLP1R is linked to pancreatic neoplasm.